Structural determination of Streptococcus pyogenes M1 protein interactions with human immunoglobulin G using integrative structural biology.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
01 2021
Historique:
received: 15 07 2020
accepted: 24 11 2020
revised: 20 01 2021
pubmed: 8 1 2021
medline: 18 5 2021
entrez: 7 1 2021
Statut: epublish

Résumé

Streptococcus pyogenes (Group A streptococcus; GAS) is an important human pathogen responsible for mild to severe, life-threatening infections. GAS expresses a wide range of virulence factors, including the M family proteins. The M proteins allow the bacteria to evade parts of the human immune defenses by triggering the formation of a dense coat of plasma proteins surrounding the bacteria, including IgGs. However, the molecular level details of the M1-IgG interaction have remained unclear. Here, we characterized the structure and dynamics of this interaction interface in human plasma on the surface of live bacteria using integrative structural biology, combining cross-linking mass spectrometry and molecular dynamics (MD) simulations. We show that the primary interaction is formed between the S-domain of M1 and the conserved IgG Fc-domain. In addition, we show evidence for a so far uncharacterized interaction between the A-domain and the IgG Fc-domain. Both these interactions mimic the protein G-IgG interface of group C and G streptococcus. These findings underline a conserved scavenging mechanism used by GAS surface proteins that block the IgG-receptor (FcγR) to inhibit phagocytic killing. We additionally show that we can capture Fab-bound IgGs in a complex background and identify XLs between the constant region of the Fab-domain and certain regions of the M1 protein engaged in the Fab-mediated binding. Our results elucidate the M1-IgG interaction network involved in inhibition of phagocytosis and reveal important M1 peptides that can be further investigated as future vaccine targets.

Identifiants

pubmed: 33411763
doi: 10.1371/journal.pcbi.1008169
pii: PCOMPBIOL-D-20-01263
pmc: PMC7817036
doi:

Substances chimiques

Antigens, Bacterial 0
Bacterial Outer Membrane Proteins 0
Carrier Proteins 0
Immunoglobulin G 0
Virulence Factors 0
streptococcal M protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1008169

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Mol Biosyst. 2014 Jul;10(7):1698-708
pubmed: 24525632
Annu Rev Biophys Biomol Struct. 2000;29:291-325
pubmed: 10940251
Curr Top Microbiol Immunol. 2013;368:1-27
pubmed: 23242849
Nat Methods. 2015 Mar;12(3):258-64, 7 p following 264
pubmed: 25599550
Nat Rev Microbiol. 2003 Dec;1(3):219-30
pubmed: 15035026
Nucleic Acids Res. 2019 Jul 2;47(W1):W423-W428
pubmed: 31114872
J Immunol. 1985 Oct;135(4):2589-92
pubmed: 4031496
Nat Commun. 2019 Jan 14;10(1):192
pubmed: 30643114
Structure. 1995 Mar 15;3(3):265-78
pubmed: 7788293
Biochem J. 2013 Oct 1;455(1):107-18
pubmed: 23865566
J Chem Theory Comput. 2017 Jun 13;13(6):3031-3048
pubmed: 28430426
Sci Rep. 2018 Oct 31;8(1):16126
pubmed: 30382169
J Exp Med. 2012 Dec 17;209(13):2367-81
pubmed: 23230002
Structure. 2013 Oct 8;21(10):1735-42
pubmed: 24035711
Nat Commun. 2019 Jun 21;10(1):2727
pubmed: 31227708
J Comput Chem. 2005 Dec;26(16):1701-18
pubmed: 16211538
J Biol Chem. 2014 Jun 27;289(26):18175-88
pubmed: 24825900
J Proteome Res. 2016 Jul 1;15(7):2143-51
pubmed: 27224449
Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W244-8
pubmed: 15980461
J Immunol. 1984 Aug;133(2):969-74
pubmed: 6234364
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Hum Vaccin Immunother. 2018;14(8):2034-2052
pubmed: 29873591
EMBO J. 2002 Apr 2;21(7):1607-15
pubmed: 11927545
Biopolymers. 1992 May;32(5):523-35
pubmed: 1515543
EMBO J. 2001 Jun 15;20(12):3046-55
pubmed: 11406581
Curr Opin Struct Biol. 2006 Apr;16(2):183-93
pubmed: 16546374
Med Microbiol Immunol. 2020 Jun;209(3):265-275
pubmed: 32072248
Microbiologyopen. 2015 Oct;4(5):774-89
pubmed: 26175306
Sci Rep. 2018 Sep 12;8(1):13673
pubmed: 30209260
Proc Natl Acad Sci U S A. 1989 Jun;86(12):4741-5
pubmed: 2660147
Biochemistry. 1981 Apr 28;20(9):2361-70
pubmed: 7236608
BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):141
pubmed: 30999854
Nat Methods. 2020 Jul;17(7):665-680
pubmed: 32483333
Anal Biochem. 2001 Jun 15;293(2):194-203
pubmed: 11399032
BMC Bioinformatics. 2016 Jan 20;17 Suppl 2:13
pubmed: 26823083
J Immunol. 1984 Jun;132(6):3091-7
pubmed: 6233367
Nature. 2011 Apr 7;472(7341):64-8
pubmed: 21475196

Auteurs

Hamed Khakzad (H)

Équipe Signalisation Calcique et Infections Microbiennes, École Normale Supérieure Paris-Saclay, Gif-sur-Yvette, France.
Institut National de la Santé et de la Recherche Gif-sur-Yvette, France.

Lotta Happonen (L)

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.

Yasaman Karami (Y)

Structural Bioinformatics Unit, Department of Structural Biology and Chemistry, C3BI, Institut Pasteur, CNRS UMR3528, Paris, France.

Sounak Chowdhury (S)

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.

Gizem Ertürk Bergdahl (GE)

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.

Michael Nilges (M)

Structural Bioinformatics Unit, Department of Structural Biology and Chemistry, C3BI, Institut Pasteur, CNRS UMR3528, Paris, France.

Guy Tran Van Nhieu (G)

Équipe Signalisation Calcique et Infections Microbiennes, École Normale Supérieure Paris-Saclay, Gif-sur-Yvette, France.
Institut National de la Santé et de la Recherche Gif-sur-Yvette, France.

Johan Malmström (J)

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.

Lars Malmström (L)

Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH